{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:41:22Z","timestamp":1790606482155,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijcard.2019.01.082","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T22:10:46Z","timestamp":1548713446000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Arterial hypertension in cancer: The elephant in the room"],"prefix":"10.1016","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-152X","authenticated-orcid":false,"given":"Giacomo","family":"Tini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Sarocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0635-4921","authenticated-orcid":false,"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Arboscello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ghigliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2127-7351","authenticated-orcid":false,"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.01.082_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0010","first-page":"e28","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics\u20142014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0015","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(75)91826-7","article-title":"High blood-pressure: a risk factor for cancer mortality?","volume":"1","author":"Dyer","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12885-016-2122-7","article-title":"Associations between metabolic disorders and risk of cancer in Danish men and women \u2013 a nationwide cohort study","volume":"16","author":"Berger","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/HJH.0000000000000770","article-title":"Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts","volume":"34","author":"Harding","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.jhh.1001834","article-title":"Cancer pattern among hypertensive patients in North Karelia, Finland","volume":"19","author":"Lindgren","year":"2005","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0045","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/HYPERTENSIONAHA.113.02953","article-title":"Hypertension and obesity and the risk of kidney cancer in two large cohorts of US men and women","volume":"63","author":"Sanfilippo","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0050","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000753","article-title":"Hypertension and subsequent genitourinary and gynecologic cancers risk: a population-based cohort study","volume":"94","author":"Sun","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0055","doi-asserted-by":"crossref","first-page":"44877","DOI":"10.1038\/srep44877","article-title":"Hypertension and breast cancer risk: a systematic review and meta-analysis","volume":"20","author":"Han","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0060","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.annepidem.2011.07.007","article-title":"The metabolic syndrome and risk of prostate cancer in Italy","volume":"21","author":"Pelucchi","year":"2011","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.metabol.2014.10.008","article-title":"Metabolic syndrome and risk of cancer: which link?","volume":"64","author":"Mendon\u00e7a","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0070","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: a systematic review and meta-analysis","volume":"35","author":"Esposito","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.diabet.2015.04.006","article-title":"The metabolic syndrome and cancer: is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?","volume":"41","author":"Harding","year":"2015","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0080","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0085","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0090","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0100","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clgc.2016.12.016","article-title":"Angiotensin inhibitors as treatment of sunitinib\/pazopanib-induced hypertension in metastatic renal cell carcinoma","volume":"15","author":"Penttil\u00e4","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/eurheartj\/ehq382","article-title":"Twisting arms to angiotensin receptor blockers\/antagonists: the turn of cancer","volume":"32","author":"Volpe","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/clc.22394","article-title":"Reducing cardiovascular and cancer risk: how to address global primary prevention in clinical practice","volume":"38","author":"Battistoni","year":"2015","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0115","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology, cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0120","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2017.06.001","article-title":"Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention","volume":"263","author":"Masoudkabir","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/clc.22885","article-title":"Inflammatory residual risk: an emerging target to reduce cardiovascular disease?","volume":"41","author":"Volpe","year":"2018","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0130","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0135","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy\u2013induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2019.01.082_bb0140","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.2459\/JCM.0000000000000381","article-title":"A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology","author":"Spallarossa","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0145","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0150","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-08-3392","article-title":"Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma","volume":"107","author":"Moser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0155","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0160","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0165","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","article-title":"Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma","volume":"8","author":"Szmit","year":"2014","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0170","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijcard.2016.09.046","article-title":"Management and research in cancer treatment-related cardiovascular toxicity: challenges and perspectives","volume":"224","author":"Cautela","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0175","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor\u2013associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0180","doi-asserted-by":"crossref","first-page":"379252","DOI":"10.1155\/2013\/379252","article-title":"Incidence of new-onset hypertension in cancer patients: a retrospective cohort study","volume":"2013","author":"Fraeman","year":"2013","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0185","first-page":"246","article-title":"Hypertension in patients with cancer","volume":"104","author":"Souza","year":"2015","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer","volume":"6","author":"Rehman","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0195","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0200","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017745819","article-title":"Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes","volume":"10","author":"Cavo","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0205","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0210","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/annonc\/mdl372","article-title":"Components of the metabolic syndrome in long-term survivors of testicular cancer","volume":"18","author":"Haugnes","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0220","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0225","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0230","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11936-016-0452-z","article-title":"Anti-VEGF induced hypertension: a review of pathophysiology and treatment options","volume":"18","author":"Brinda","year":"2016","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0250","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0260","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.11.174","article-title":"Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond","volume":"227","author":"Di Lisi","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0270","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11936-017-0524-8","article-title":"Cardiovascular complications of targeted therapies for chronic myeloid leukemia","volume":"19","author":"Damrongwatanasuk","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0280","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0285","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0290","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0295","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: clinical presentation and molecular understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0300","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0305","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/ijms18030625","article-title":"The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors","volume":"18","author":"Ancker","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0310","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.117.09275","article-title":"Hypertension and VEGF (vascular endothelial growth factor) receptor tyrosine kinase inhibition: effects on renal function","author":"Boursiquot","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.gore.2016.06.002","article-title":"Bevacizumab induced hypertension in gynecologic cancer: does it resolve after completion of therapy?","volume":"17","author":"Corr","year":"2016","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0320","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0325","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","article-title":"The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors","volume":"15","author":"Tocchetti","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000045","article-title":"Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer","volume":"1","author":"Dion\u00edsio de Sousa","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0335","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cam4.701","article-title":"Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer","volume":"5","author":"Nakaya","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116527","article-title":"Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer","volume":"10","author":"Feliu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0345","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Donskov","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0350","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13104-016-1895-8","article-title":"The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study","volume":"9","author":"Miyake","year":"2016","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0355","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of cardiovascular toxicity by proteasome inhibitors: new paradigm derived from clinical and pre-clinical evidence","volume":"828","author":"Gavazzoni","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11936-018-0618-y","article-title":"Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention","volume":"20","author":"Lee","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0365","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0370","doi-asserted-by":"crossref","first-page":"23704","DOI":"10.18632\/oncotarget.25281","article-title":"Efficacy and safety of carfilzomib in relapsed and\/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials","volume":"9","author":"Shah","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0375","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clml.2016.01.008","article-title":"Management of carfilzomib-associated cardiac adverse events","volume":"16","author":"Mikhael","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0380","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0385","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0390","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0395","first-page":"821","article-title":"PI3K inhibitors: understanding toxicity mechanisms and management","volume":"31","author":"Greenwell","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0400","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.ijcard.2013.01.052","article-title":"Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors","volume":"167","author":"Conti","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0405","series-title":"Manual of Cardio-oncology","first-page":"443","article-title":"What the oncologist needs to know: how to ask for a cardiology consultation","author":"Spallarossa","year":"2017"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0410","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fphar.2017.00100","article-title":"Current situation of medication adherence in hypertension","volume":"8","author":"Vrijens","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0415","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijcard.2017.12.026","article-title":"Is early and fast blood pressure control important in hypertension management?","volume":"254","author":"Volpe","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0420","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/taap.2002.9532","article-title":"Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy","volume":"185","author":"Santos","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0425","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0430","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0435","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0445","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2019.01.082_bb0450","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.2459\/JCM.0000000000000383","article-title":"A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology","author":"Maurea","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0455","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0460","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2011.03.033","article-title":"The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer","volume":"47","author":"Bamias","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0465","doi-asserted-by":"crossref","first-page":"67661","DOI":"10.18632\/oncotarget.11813","article-title":"Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijcard.2019.01.082_bb0470","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40292-017-0216-1","article-title":"Monotherapy and dual combination therapies based on olmesartan: a comprehensive strategy to improve blood pressure control","volume":"24","author":"Volpe","year":"2017","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0475","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40292-017-0239-7","article-title":"Personalised single-pill combination therapy in hypertensive patients: an update of a practical treatment platform","volume":"24","author":"Volpe","year":"2017","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"10.1016\/j.ijcard.2019.01.082_bb0480","series-title":"Cardiovascular Complications in Cancer Therapy. Current Clinical Pathology","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-93402-0_11","article-title":"Arterial hypertension","author":"Spallarossa","year":"2019"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318355682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318355682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:01:07Z","timestamp":1606262467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318355682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":93,"alternative-id":["S0167527318355682"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.082","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arterial hypertension in cancer: The elephant in the room","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}